Xenon Pharmaceuticals
XENE
203 hedge funds and large institutions have $2.95B invested in Xenon Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 24 closing their positions.
321% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $1.13M
23% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 62
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% more capital invested
Capital invested by funds: $2.89B → $2.95B (+$57.8M)
0.56% more ownership
Funds ownership: 98.28% → 98.84% (+0.56%)
5% less funds holding
Funds holding: 213 → 203 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$60.8M |
| 2 |
JP Morgan Chase
New York
|
+$36.5M |
| 3 |
SC
Samlyn Capital
New York
|
+$15.3M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$12.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$79.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$26.2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$14.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.6M |
| 5 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$9.77M |
XENE Hedge Fund Activity: Q3 2024 in Review
203 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2024, worth a combined $2.95B — up 2% from $2.89B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of XENE and 14 opened new positions — a net loss of 10 holders — while 62 trimmed existing stakes and 76 added.
The largest buyer was Janus Henderson Group, adding an estimated $60.8M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $79.7M sold.
- 203 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2024, down from 213 in Q2 2024.
- Funds reported $2.95B of Xenon Pharmaceuticals stock for Q3 2024, up 2% quarter-over-quarter.
- 14 funds opened new Xenon Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of -10 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2024 was Janus Henderson Group, an estimated $60.8M added.
- The largest Xenon Pharmaceuticals seller in Q3 2024 was Paradigm Biocapital Advisors, an estimated $79.7M sold.
Based on aggregated 13F filings for Q3 2024.